Cross-sectoral Rehabilitation for Patients With Intermittent Claudication

November 20, 2018 updated by: Maj Siercke Bergstedt, Rigshospitalet, Denmark

Cross-sectoral Rehabilitation for Patients With Intermittent Claudication: Effects and Patient Experience - The CIPIC-Rehab Study (Cross-sectoral Intervention for Patients With Intermittent Claudication)

Exercise training combined with other lifestyle changes are essential elements in conservative management of patients with Intermittent Claudication (IC). IC is essentially caused by atherosclerosis, which reduces blood flow to the legs and leads to cramping leg pain when walking. Patients suffering from IC may have difficulty in exercising and changing lifestyle without systematic intervention despite the risk of morbidity, mortality and hospitalization. Today, rehabilitation programs, including supervised exercise, exist for patients suffering ischemic heart disease but not for patients with IC, despite evidence that exercise therapy is highly beneficial for patients suffering IC.

The overall aim of the present study is to examine the effect of conservative management of patients with IC provided as a three month, cross-sectoral exercise and lifestyle intervention program based on the already established cardiac rehabilitation program. Outcome will be assessed on walking distance and secondly on lifestyle changes and patient reported outcomes.

Implications:

The project will provide evidence for the effect of cross-sectoral collaborative conservative management of patients with IC, using the existing rehabilitation program already offered to patients suffering ischemic heart disease. Moreover, it will elicit knowledge on patient perceptions of conservative management of IC provided as a proactive cross-sectoral intervention and ways to support patients with IC in adhering to conservative management.

Study Overview

Status

Unknown

Detailed Description

Main study:

Randomized Clinical Trial comparing Cross-sectoral Training Intervention for Patients with Intermittent Claudication with standard care.

Patients will be randomized to the intervention or control group using a computer-generated block randomized allocation scheme.

Sample size:

The expected average base line value of maximal walking distance (MWD) has been set to 120 m and the investigators want to detect a 50% improvement (60 m). There is a wide variance in MWD in this patient group, and consequently the standard deviation (SD) is set at 100 m. With a 5% significance level and 80% power, it will thus be necessary to include 88 patients to detect an improvement of 60 m in MWD in the intervention group at 12-months follow-up, compared to the control group. Owing to the previously mentioned risk of comorbidities, combined with an expected loss to follow-up, a drop-out of 25% must be expected, wherefore the investigators plan is to include 118 patients in total (59 in each group).

Baseline data:

The following data will be collected at inclusion, before randomization:

Demography (age, gender, housing, marital status, socioeconomic status, level of education) Height and weight will be combined to report body mass index (BMI) in kg/m^2, waist circumference, blood pressure.

Cardiovascular risk factors, co-morbidity (Charlson Comorbidity Index), current medications, blood samples (biomarkers, cholesterol, HBa1C), based on consultation measurements.

Lifestyle: Measured by self-reported smoking behavior, daily physical activity: minimum 30 min. walking time daylit or other exercise activity, self-reported Diet Registration and alcohol consumption.

Quality of life: Measured using the Vascu-Quality of Life questionnaire (VascuQol).

Depression and anxiety measured with the Hospital Anxiety and Depression Scale (HADS).

Assessment of patients' individual competencies for self-management is measured by using The Patient Activation Measure" (PAM13).

Maximum walking distance (MWD) and pain-free walking distance (PWD) measured using the standardized Treadmill Walking Test, and Visual Analog Score for pain. Follow-up Treadmill Walking Test is performed by a research assistant for whom it is blinded if patients are in intervention or control group.

Control group - standard care. Patients randomized to the control group will initially receive brief advice regarding exercise therapy (walking), smoking cessation, and preventive medical treatment with antiplatelet therapy and statin. Written information about medication, walking exercise, and a logbook for self-reporting of walking behavior is handed out to the IC patients in the outpatient clinic at the Department of Vascular Surgery, Rigshospitalet.

The intervention group will initially receive individual brief advice regarding exercise therapy, smoking cessation advice/course offerings, and preventive medication with antiplatelet therapy and statin in the outpatient clinic at the Department of Vascular Surgery. Patients will receive written standard information and a pedometer and be asked to self-report walking behavior in a logbook.

In the municipality the intervention group will participate in Supervised Exercise Training and education. This entails that patients will actively engage in groups of 8-10 in 24 supervised physical exercise sessions, each lasting one hour with two weekly sessions. Physiotherapists in the training Centre will supervise participants' training. The exercises include varied forms of physical exercise.

The physiotherapists will measure 6 minutes walking test and chair- stand- test prior to and at completion of the intervention and use the results as a part of an individual motivational interview with each patient after completion of the 24 training sessions. Furthermore, participants will be advised in group sessions by the principle investigator, in a 2-hour long session, about the pathophysiology of IC, medications, lifestyle factors, disease management, quality of life and how to cope with the disease. A clinical dietician will advise participants in a 2-hour long session about healthy diet and atherosclerosis. In addition, participants have access to a 2-4 hour long individual consultation with a dietician. After completion of exercise training, participants are offered personalized motivational follow-up text messages. Content, frequency and duration of the text messages are agreed upon individually for the next 8 months and will be reassessed at 3 and 6-months follow-up.

Sub-study. Qualitative Study. Individual brief interview and questionnaire survey supplemented with focus group interviews of patients participating in the intervention group in the randomized clinical study. A protocol for the study will be drawn up in accordance with the "Consolidated Criteria for Reporting Qualitative Research" (COREQ).

An interview guide will be developed prior to interviewing. The investigators expect to explore the following tentative issues: Patient experiences of the training and teaching sessions, factors facilitating or hindering lifestyle changes, how the use of pedometer, logbook and text messages influenced motivation/adherence, patient satisfaction with the intervention and suggestions for future rehabilitation programs.

Study Type

Interventional

Enrollment (Anticipated)

118

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Copenhagen, Denmark, 2100
        • Dept. of Vascular Surgery, Rigshospitalet, University of Copenhagen.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with newly diagnosed Intermittent Claudication, referred to dept. of vascular surgery and offered conservative management.
  • Citizens in the municipalities of the study.
  • Able to understand, read and speak Danish.
  • Able to perform physical exercise and informed consent to participate in the trial.

Exclusion Criteria:

  • Patients that needs vascular surgery.
  • Co-morbidity that hinder participation and to perform physical exercise.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
NO_INTERVENTION: Control group
Usual care. Conservative management of IC
EXPERIMENTAL: Intervention
Supervised exercise
Supervised exercise training as a conservative management of intermittent claudication in a community setting based on cardiac rehabilitation program

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum Walking Distance on a treadmill
Time Frame: 12 months
Change from Baseline Maximum Walking Distance at 12 months. Detect an improvement of 60 meters in Maximum Walking Distance in the intervention group compared to the control group, using the standardized Treadmill Walking Test.
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain-free walking distance on a treadmill
Time Frame: 12 months
Change of Pain-free walking distance (PWD) in meters, measured using the standardized Treadmill Walking Test compared to the control group.
12 months
Quality of Life Measurement
Time Frame: 12 months
Quality of Life questionnaire (VascuQol). Change from Baseline score at 12 months compared to the control group. 6 questions - level of pain, walking capacity and social activity associated with Intermittent claudication.
12 months
Depression and anxiety Measurement
Time Frame: 12 months
Hospital Anxiety and Depression Scale (HADS).Change from Baseline score at 12 months. Score 0-21. Lowest possible score is better.
12 months
Self-management Measurement
Time Frame: 12 months
The Patient Activation Measure (PAM13).Change from Baseline score at 12 months. More or less activation compared to the control group. More activation is better.
12 months
smoking cessation Measurement
Time Frame: 12 months
Change from Baseline score at 12 months.Smoking cessation or not.
12 months
Daily physical activity Measurement
Time Frame: 12 months
Change from Baseline score at 12 months. More or less active. Minimum 30 min. walking daily.
12 months
Diet Registration Measurement
Time Frame: 12 months
Change from Baseline score at 12 months. More or less healthy diet. Healthy diet score change to a higher percentage where 75% is healthy diet.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Selina Kikkenborg Berg, Professor, University of Copenhagen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

December 5, 2017

Primary Completion (ANTICIPATED)

June 1, 2020

Study Completion (ANTICIPATED)

September 1, 2020

Study Registration Dates

First Submitted

October 25, 2018

First Submitted That Met QC Criteria

November 2, 2018

First Posted (ACTUAL)

November 5, 2018

Study Record Updates

Last Update Posted (ACTUAL)

November 21, 2018

Last Update Submitted That Met QC Criteria

November 20, 2018

Last Verified

November 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intermittent Claudication

Clinical Trials on Supervised exercise training

Subscribe